Abstract:Peptidyl-prolyl isomerases catalyze the conversion between cis and trans isomers of proline. The cyclophilin family of peptidyl-prolyl isomerases is well known for being the target of the immunosuppressive drug cyclosporin, used to combat organ transplant rejection. There is great interest in both the substrate specificity of these enzymes and the design of isoform-selective ligands for them. However, the dearth of available data for individual family members inhibits attempts to design drug specificity; additionally, in order to define physiological functions for the cyclophilins, definitive isoform characterization is required. In the current study, enzymatic activity was assayed for 15 of the 17 human cyclophilin isomerase domains, and binding to the cyclosporin scaffold was tested. In order to rationalize the observed isoform diversity, the high-resolution crystallographic structures of seven cyclophilin domains were determined. These models, combined with seven previously solved cyclophilin isoforms, provide the basis for a family-wide structure:function analysis. Detailed structural analysis of the human cyclophilin isomerase explains why cyclophilin activity against short peptides is correlated with an ability to ligate cyclosporin and why certain isoforms are not competent for either activity. In addition, we find that regions of the isomerase domain outside the proline-binding surface impart isoform specificity for both in vivo substrates and drug design. We hypothesize that there is a well-defined molecular surface corresponding to the substrate-binding S2 position that is a site of diversity in the cyclophilin family. Computational simulations of substrate binding in this region support our observations. Our data indicate that unique isoform determinants exist that may be exploited for development of selective ligands and suggest that the currently available small-molecule and peptide-based ligands for this class of enzyme are insufficient for isoform specificity.

1.88 Å crystal structure of the C domain of hCyP33: A novel domain of peptidyl-prolyl cis–trans isomerase

Structure of recombinant human cyclophilin J, a novel member of the cyclophilin family.

Biochemical Features of Recombinant Human Cyclophilin J

Structural and Biochemical Characterization of the Human Cyclophilin Family of Peptidyl-Prolyl Isomerases

Discovery of a Potent Peptidic Cyclophilin A Inhibitor Trp-Gly-Pro

Cyclophilin A (cypa) Induces Chemotaxis Independent of Its Peptidylprolyl Cis-Trans Isomerase Activity

The Role of Cyclophilins in Viral Infection and the Immune Response

Cyclophilin A peptidyl-prolyl isomerase activity promotes ZPR1 nuclear export

Cyclophilin A Facilitates HIV-1 DNA Integration

The crystal structure of Helicobacter cysteine-rich protein C at 2.0 A resolution: similar peptide-binding sites in TPR and SEL1-like repeat proteins

Characterization of Interaction Between C-domain on HIV-1 Gp41 and the Putative Receptor Protein P62.

Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics

Cyclophilin J Is a Novel Peptidyl-Prolyl Isomerase and Target for Repressing the Growth of Hepatocellular Carcinoma

Structure of the Autocatalytic Cysteine Protease Domain of Potyvirus Helper-Component Proteinase

Cyclophilin J PPIase Inhibitors Derived from 2,3-Quinoxaline-6 Amine Exhibit Antitumor Activity

Crystallization and Preliminary X-ray Crystallographic Analysis of the Human CKIP-1 Pleckstrin Homology Domain.

Emerging role of cyclophilin A in HIV-1 infection: from producer cell to the target cell nucleus

Crystal Structure of the C-terminal Deaminase Domain of APOBEC3G: Implications and Projections

Crystallization and Preliminary X-ray Crystallographic Studies of Human Cyclophilin J.

Cyclic Peptide Inhibitors of HIV-1 Capsid-Human Lysyl-Trna Synthetase Interaction.

[Expression, Purification and Characterization of Recombinant Human Cyclophilin A].